>> Continued From the Previous Page <<
According to Dr. Mary Talley Bowden, “In the appellate hearing for United States ex rel. Jackson v. Ventavia Research Group, LLC, whistleblower Brook Jackson challenged the district court’s decision to allow the U.S. government to intervene and dismiss her qui tam lawsuit under the False Claims Act (FCA).”
Jackson’s 81-page complaint paints a disturbing picture of trial sites in Texas where chaos, shortcuts, and fabricated paperwork became routine. She describes fraud and safety violations occurring “on an almost daily basis.”
Her claims include falsified patient records, unqualified staff injecting trial subjects, and critical safety requirements completely ignored. Jackson says even pregnant women and family members—explicitly barred by protocol—were injected anyway.
When she discovered the scale of the violations, Jackson contacted the FDA hotline on September 25, 2020. Hours later, she was terminated. Ventavia brushed off her allegations by claiming she was “not a good fit.”
No corrective action followed.
The complaint notes that Pfizer had enormous financial motivation to overlook trial fraud. The company was set to receive $1.95 billion for the first 100 million shots, with the Pentagon later exercising an option that doubled the payout to $3.9 billion.
Jackson’s lawsuit argues that Pfizer and its partners knowingly submitted falsified data to the federal government and retaliated against her for reporting it.
Attorney Warner Mendenhall said the DOJ’s own courtroom arguments inadvertently proved the whistleblower’s point.
“The government really sort of made our case for us…”
He warned the judges that the FDA’s recent admission of child deaths indicates the agency is preparing to recognize far more.
The Biden administration originally said it would not dismiss Jackson’s case. Months later, after aligning itself with Pfizer, the DOJ reversed course.
Government lawyers argued that:
Even if 3 percent of the trial data were fraudulent…
Even if Pfizer misled regulators…
Even if Jackson was correct on every point…
The vaccine still would have been approved.
This stance stunned observers, because it implies that fraud, safety violations, and fabricated data are irrelevant so long as the government supports the product.
According to courtroom summaries, DOJ attorney Nicole Smith refused to address the leaked internal FDA memo from CBER Director Vinay Prasad, which acknowledged approval standards must be raised after the agency counted multiple child deaths.
Mendenhall pushed back hard, arguing that Congress never intended whistleblower cases to be dismissed simply because the government wished them away. He insisted that Jackson provided evidence—including data showing more deaths in the vaccine arm—that warranted a full investigation.
The Biden DOJ disagreed. Government attorney Sarah Smith argued that under Supreme Court precedent, the DOJ’s decision to end the case is enough reason to shut it down permanently. She said dismissal with prejudice was appropriate to prevent Jackson from trying again.
Jackson’s team urged the appeals court to send the case back and require the government to show genuine “good cause”—not political preference—for taking over and killing the lawsuit.
He warned that giving the DOJ unchecked power to shut down whistleblowers would send a dangerous message: that exposing government-aligned fraud is pointless.
As the FDA prepares for a reckoning over child deaths linked to the COVID shot, the Biden administration appears more determined than ever to ensure that no courtroom, jury, or public hearing gets the chance to ask what Pfizer knew—and when they knew it.
